COMPANY

We contribute to promoting human health.
We are the global leader in stem cell therapies

  • HOME
  • COMPANY
  • EHL BIO History
  • Vision
  • 2024

    1) Approval of Phase 2 clinical trial for KDSTEM(Chronic kidney disease, Urine-derived SC)
    2) Complete Phase 3 clinical trial for ADSTEM(Atopy dermatitis, Adipose-derived SC)
    3) Complete phase 1 clinical trial for rotator cuff tear
    4) Complete advanced regenerative medicine clinical trial using 3 types immune cells(NK, T, DC)

  • 2023

    1) Start Phase 3 clinical trial for ADSTEM(Atopy dermatitis, Adipose-derived SC)
    2) Start phase 1 clinical trial for rotator cuff tear
    3) Complete Phase 1 clinical trial for KDSTEM(Chronic kidney disease, Urine-derived SC)

  • Now
  • 2022

    - Start Phase 1 clinical trial using Urine-derived Stem cells,
    - Complete Phase 2 clinical trial for ADSTEM(Atopy dermatitis, Adipose-derived SC),
    - Selected as a target for the government-wide regenerative medical technology development project,
    - Signed MOU for advanced regenerative medicine(Hwasun Chonnam National University Hospital)
    - IPO(Initial public offering)
    - Start advanced regenerative medicine clinical trial using 3 types immune cells(NK, T, DC)

  • 2021

    - Permission for human cell management business(No. 1)
    - CPC(Cell Processing Center) Permission for the 1st time in Korea
    - Signed MOU for advanced regenerative medicine
    (Chungnam National University Hospital, Dankook University Hospital
    Chonnam National University Hospital, Seoul Songdo Hospital)

  • 2020

    Establishment of subsidiary EHL CELLTECH

    JAN
  • 2019

    Phase 2 clinical trials approval for
    ADSTEM(the first in Korea, self adipose-derived, intravenous injection)
    Opening of a Cambodian branch and a hospital specializing
    in cell therapy(Joint company)
    Completion of 2nd GMP(500 LOT per month can be cultured.)
    Opening a local office in Indonesia

    OCT MAR
  • 2018

    Phase 2 clinical trials application for ADSTEM
    Establishment of Stem-heal Society.

    DEC JAN
  • 2017

    2017.12 Phase 1 clinical trials completed for ADSTEM.
    2017.11 Signed ODA Clinic for Cooperation in Japan.
    2017.09 Establishment of representative office in Vietnam
    2017.07 CPC approval by the Japanese Ministry of Health and welfare.
    2017.06 Safety test completed for immune cell preclinical test.

    DEC NOV SEP JUL JUN
  • 2016

    Selected for Start-up Growth Technology Development Project
    by Ministry of SMEs(Small and Medium-sized Enterprises) and startups.

    Preclinical test for immune cell.
    Approved Clinic Phase I

    NOV OCT MAY
  • 2015

    Applying for clinical trials of Self adipose-derived
    stem cells/Vascular injection/Atopic dermatitis.
    Expand and relocate research institutes.
    Certified as Venture Company(‘15.03)

    DEC NOV MAR
  • 2014

    Registered Company Research Center
    Selected for Industry-Academic Cooperation Technology Development
    Projects of Ministry of SMEs(Small and Medium-sized Enterprises) and startups.

    Preclinical test for ADSTEM injection that is atopic dermatitis treatment.

    DEC OCT MAY
  • 2013

    Launch of stem cell culture fluid cosmetics, hair growth test by culture fluid,
    research for development of culture medium for healthcare.

    APR
  • 2012

    Founded EHL Bio, Co., Ltd

    FEB